£100k-a-year cancer drugs ‘have little effect on life expectancy’ : dailymail

referring to dailymail

£100k-a-year cancer drugs 'have little effect on life expectancy'

£100k-a-year cancer drugs 'have little effect on life expectancy'

Expensive new cancer drugs are contributing little to the life expectancy of dying patients, an expert has warned.Despite billions of pounds of investment, most extend the lives of patients by a few months at best, according to analysis published in the British Medical Journal last night.Dr Peter Wise, a retired consultant physician from Charing Cross Hospital in London, claims drug development has contributed little to the improvements in cancer life expectancy seen in recent decades.The world's biggest drug firms make huge sums from cancer drugs, with the most expensive treatments costing more than £100,000 a year.


furthermore whnt

Toddler battling cancer 'rose from the dead' after doctors took him off life support

Toddler battling cancer 'rose from the dead' after doctors took him off life support

DERBY, England – A 3-year-old boy from England made a miraculous recovery after he was taken off life support, according to The Telegraph.Last Christmas, Dylan Askin was rushed to the hospital when his lungs collapsed.For several weeks, he was in and out of the emergency room as doctors tried to figure out what was wrong.Finally, he was diagnosed with a rare form of lung cancer that caused cysts to appear on his lungs, and he began receiving chemotherapy.


not to mention telegraph

Hospitals wasting money on expensive cancer drugs that only prolong life by two months, specialist argues

Hospitals wasting money on expensive cancer drugs that only prolong life by two months, specialist argues

Hospitals are "unethically" wasting money on highly expensive cancer drugs that only prolong life by one or two months, an article in the British Medical Journal warns.Despite a spending bill of billions, new drugs approved in the past 10 years often have only a minor effect on survival in adults with the disease, argues cancer specialist Dr Peter Wise.The former NHS consultant oncologist said prescribing medicines that cost a six figure sum but which only prolong life by a few weeks "may be inappropriate" for many patients, and calls for stricter drug approval criteria.Global sales of cancer drugs in were around £85 billion in 2015, with the NHS's own Cancer Drugs Fund allocating £340 million, on top of mainstream hospital spending, in the last financial year.